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Cerebellar Dysfunction in Multiple 
Sclerosis
Alastair Wilkins*
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Multiple sclerosis (MS) commonly affects the cerebellum causing acute and chronic 
symptoms. Cerebellar signs contribute significantly to clinical disability, and symptoms 
such as tremor, ataxia, and dysarthria are particularly difficult to treat. Increasing knowl-
edge concerning the pathophysiology of cerebellar disease in MS from human postmor-
tem studies, experimental models, and clinical trials has raised the hope that cerebellar 
symptoms will be better treated in the future.
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inTRODUCTiOn TO MULTiPLe SCLeROSiS (MS)
Multiple sclerosis is an inflammatory disease of the central nervous system of unknown etiology. 
Typically patients have an initial relapsing and remitting course [relapsing remitting MS (RRMS)] 
followed by, in the majority of case, secondary progressive MS (SPMS) during which patients 
develop slow, insidious accumulation of disability (1). A small percentage of patients with MS have 
progressive disability from onset [primary progressive MS (PPMS)]. Despite extensive research 
and increasing knowledge of pathophysiological mechanisms, there is still no cure for the disease. 
Significant advances in therapeutics have occurred, and novel therapies, including natalizumab, 
alemtuzumab, fingolimod, and dimethyl fumarate have important disease-modifying effects (2).
The cerebellum and its efferent and afferent pathways are commonly affected in MS; and cerebel-
lar ataxia is a common symptom of the disease, particularly in progressive disease (3, 4). Despite 
affecting the entire central nervous system, there are aspects of cerebellar involvement in MS that 
warrant specific attention and may give important insights into potential mechanisms and treat-
ments for progressive disease. Within this review clinical aspects, pathological changes, monitoring 
of cerebellar changes in MS, and treatments for cerebellar disease will be discussed. In addition, 
various experimental models of cerebellar inflammation will be reviewed and how they may inform 
on future potential therapies.
CLiniCAL FeATUReS OF CeReBeLLAR DYSFUnCTiOn in MS
Coordination problems are common in MS and occur predominantly due to pathology within the 
cerebellum itself or impairment in cerebellar connections, including proprioceptive afferent inputs. 
Patients with MS may present with either acute cerebellar dysfunction relating to acute relapse or 
chronic cerebellar problems in progressive disease. Cerebellar pathology may lead to limb, gait, 
and truncal ataxia, dependent on precise lesional site, as well as other cerebellar features such as 
gaze-evoked nystagmus, dysarthria, and tremor.
Involvement of the cerebellum and brainstem connections occurs during MS relapse not 
infrequently. Cerebellar relapse at disease onset also seems to be associated with increased risk of 
cerebellar involvement during subsequent relapse (5). Multivariate analyses have suggested that 
involvement of the cerebellum at onset of the disease is associated with worse prognosis [shorter 
FigURe 1 | Proteolipid protein staining of human cerebellum of a patient with 
multiple sclerosis showing extensive white matter demyelination (red), which 
extends into the gray matter.
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time to expanded disability status scale (EDSS) score 6] (6). In 
a recent database study of approximately 15,000 patients who 
experienced a total of nearly 50,000 relapses, cerebellar relapses 
accounted for approximately 10% of all relapses; being more 
frequent in men and in those with longer duration of disease 
(7). Cerebellar/brainstem relapses are also associated with poor 
relapse recovery which, in itself, is associated with earlier onset 
of progressive disease (8).
In patients with established MS, ataxia is thought to occur 
in about 80%, with symptoms particularly prevalent in those 
with progressive disease (3, 4). MS tremor is thought to arise 
predominantly as a consequence of cerebellar and/or thalamic 
disease (9). Tremor may affect limbs, trunk, vocal cords, and 
head (titubation). Intention and postural tremors are the com-
monest types, although rest and rubral tremors occur rarely 
(10, 11). Although significantly disabling, severe tremor is a 
relatively rare consequence of MS, occurring in 3% of patients 
in one study (11). Severe tremor in this study was associated 
with indicators of global disability, such as high EDSS. The 
pathophysiology of MS tremor is complex and likely to involve 
cerebellar connections, as well as cortical and basal ganglia 
connections. A pure cerebellar syndrome (in the absence of 
involvement of other parts of the central nervous system) should 
warrant the search for an alternative explanation, such as a meta-
bolic disorder or an inherited cerebellar disorder. Gait ataxia is 
thought to arise predominantly due to damage to the anterior 
lobe of the cerebellum (12). Cerebellar dysarthria appears 
uncommonly at disease onset but is common in those with 
advanced secondary progressive disease. Paroxysmal symptoms 
of MS are relatively infrequent, and paroxysmal dysarthria with 
ataxia has been reported in MS and is thought to occur due to 
midbrain  pathology (13, 14).
The intriguing role of the cerebellum in cognitive processing 
is a subject in intense research, and there is some suggestion that 
involvement of the cerebellum may be linked to defects in cogni-
tive processes in MS (15). Injury to the cerebellum (from what-
ever cause) has been linked to deficits in verbal fluency, working 
memory, and attention, as well as executive dysfunction (16). 
Interestingly, the cognitive profile of MS patients with cerebel-
lar lesions differs to those without cerebellar involvement (17). 
Reduced total cerebellar volume scores on magnetic resonance 
imaging (MRI) are associated with worse performance on cogni-
tive tests (15). Specifically, volume loss of the posterior–inferior 
cerebellum is associated with poor cognitive function, whereas 
volume loss to anterior cerebellum is associated with motor 
dysfunction (12).
In summary, cerebellar dysfunction is a feature of both 
RRMS and progressive MS leading to a range of neurological 
manifestations. In general, involvement of the cerebellum is 
linked to increased disability and worse prognosis, which, given 
the important role of cerebellar connections in motor control, is 
perhaps not surprising.
CeReBeLLAR PATHOLOgY in MS
Cerebellar white matter lesions are well described in the lit-
erature and often apparent on MRI scans of patients with MS. 
Cerebellar peduncles are common lesional sites. Demyelination 
commonly occurs in cerebellar white matter (Figure  1). In 
addition, observations concerning gray matter demyelination 
in cerebral cortex has led to studies evaluating gray matter 
disease in the cerebellum (18, 19). Indeed, the cerebellar cortex 
appears a major site for demyelination with one study report-
ing 38.7% of the cerebellar cortex being affected in a cohort of 
PPMS and SPMS patients (20). Interestingly, in this study, the 
majority of gray matter lesions appeared independent of white 
matter lesions, with some tissue blocks showing very extensive 
gray matter demyelination in the near absence of underlying 
white matter disease. Cerebellar cortical lesions are typically 
classified as leukocortical (extending from white matter into 
adjacent gray matter); intracortical (purely gray matter) arising 
around inflamed veins and venules; and subpial lesions that are 
“band-like” and parallel to the meningeal surface (20). The lat-
ter are abundant in patients with progressive MS. Observations 
concerning the relationship of subpial demyelination and 
meningeal inflammation have been suggested a possible driver 
for neurodegenerative processes in progressive MS, although 
causative proof is needed (21).
Neuronal pathology in the MS cerebellum is less well defined. 
The study by Kutzelnigg et al. (mentioned above) showed neu-
ronal pathology with some reductions in Purkinje cell density 
in lesions (compared to control) (20). No significant reductions 
in Purkinje cell densities were seen in non-lesional cerebellar 
gray matter. Our own study confirmed these observations and 
also showed changes in neurofilament phosphorylation states 
in Purkinje cells (22). We noted abnormal neurofilament phos-
phorylation with loss of dephosphorylated neurofilaments and 
increased expression of hyperphosphorylated neurofilaments. 
In addition, axonal spheroids (representing transection of the 
Purkinje cell axon) were note within leukocortical lesions, indi-
cating significant Purkinje cell pathology within the MS cerebel-
lum. Alterations in neurofilament phosphorylation states and 
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axonal transection are reported within cerebral white matter 
(23). In a further study of MS cerebellum, we showed reductions 
in neuronal and myelin markers with evidence for increased 
lipid peroxidation end products (end products of oxidative 
injury to polyunsaturated fatty acids found in cell membranes) 
(24). We also found elevation in superoxide dismutase enzyme 
expression in MS cerebellum (compared to control) but a rela-
tive lack of other antioxidant enzyme expression, suggesting a 
possible mechanism for the extensive oxidative stress-related 
injury seen.
Other changes in Purkinje cell phenotype have been docu-
mented in MS, notably changes in ion channel expression and 
receptor profiles. The Nav1.8 sensory neuron-specific sodium 
channel is normally expressed at very low levels in Purkinje 
cells, but its expression is markedly upregulated in MS (25). In 
addition, annexin light chain (p11) that facilitates the functional 
expression of this ion channel is also upregulated in Purkinje cells 
(26). In experimental models, aberrant expression of Nav1.8 in 
Purkinje cells causes significant abnormalities of firing patterns 
of these cells (27, 28).
The interesting phenomenon of Purkinje cell heterokaryon 
formation has been noted to occur in MS cerebellum (29). This 
process appears to occur almost exclusively in Purkinje cells 
within the central nervous system and denotes the appear-
ance of binucleated cells. Binucleation is thought to occur by 
cell fusion, a process by which the nucleus of a non-Purkinje 
cell is donated and integrates with the Purkinje cell (30). The 
commonest type of “donor” cell in experimental paradigms of 
cell fusion are bone marrow-derived cells, and researchers have 
postulated the donation of a foreign nucleus to the Purkinje 
cell may be a mechanism of protecting the cell from injury, 
since expression of donor cell genes occurs. In MS, binucleated 
Purkinje cells are significantly increased compared to control, 
suggesting a possible adaptive process occurring in response to 
the disease.
There still remains much to be understood about the pathol-
ogy of the cerebellum in MS; for instance, there is a paucity 
of information on processes occurring in the molecular or 
granular layers; and histopathological correlates of cerebellar 
symptoms are lacking. Many of the pathological findings in 
MS cerebellum are shared with other neurological conditions 
affecting the cerebellum (e.g., neurofilament changes; Purkinje 
cell injury). Understanding which pathological features are 
specific to MS may help design future therapies. Furthermore, 
understanding why cerebellar pathology is linked to a worse 
prognosis in the disease may help design therapies for cerebel-
lar dysfunction in MS.
MOniTORing CeReBeLLAR  
DiSeASe in MS
The major disability rating scales used in MS incorporate esti-
mations of ataxia to a variable degree. These scales are used to 
provide a semiquantitative description of disability in the disease 
and remain prominent outcome measures of new therapies in 
clinical trials. The EDSS is the most commonly used disability 
scale in MS trials, and its quantification of disability relies heavily 
on motor dysfunction (31). As part of the grading, disturbances 
of functional systems (FS), such as visual function or bowel and 
bladder function, are assessed and can contribute to the overall 
score attributed. The cerebellar system is one of the FS tested, 
and increasing levels of ataxia may contribute to the overall 
EDSS level. Other scales also incorporate cerebellar function. For 
instance, the multiple sclerosis functional composite has a 9-hole 
peg test as one of the three tests involved, which relies heavily 
on the integrity of cerebellar functioning (32). The relevance 
of specific ataxia ratings scales has not been studied in MS in 
detail. Primarily these scales have been developed for assessment 
of “pure” cerebellar or spinocerebellar syndromes, typically the 
inherited ataxias.
Magnetic resonance imaging studies have confirmed exten-
sive cerebellar involvement in both RRMS and progressive MS 
(33, 34). The revised McDonald criteria for the diagnosis of MS 
recognize infratentorial regions of the central nervous system to 
be a typical lesional site in MS (35). Recent diffusion-weighted 
MRI (DWI) techniques using a diffusion tensor model have 
changes in white matter tracts in MS, notably cerebellar pedun-
cles. One study revealed abnormalities in tractography signals 
within the superior cerebellar peduncle, which correlated with 
upper limb dysfunction in patients with PPMS (36). Indeed, 
the presence of T2 lesions within cerebellar peduncles on MRI 
was associated with cerebellar and ambulatory symptoms in a 
large imaging study (37). As stated above, cerebellar gray matter 
disease may be extensive in pathological samples. A combined 
MRI and posturography study showed that gray matter atrophy 
of the superior lobules of the cerebellum (IV, V, VI), and lobules 
VIII correlated with worse posturometric values (38). Magnetic 
resonance spectroscopy (MRS) has been used to study neuronal 
markers, typically N-acetyl aspartate, in patients with MS look-
ing for evidence of neuronal/axonal loss in progressive disease. 
Persistent cerebellar dysfunction has been linked with MRS 
markers of axonal loss in the cerebellum of patients with progres-
sive MS (39).
Other cerebellar monitoring techniques, such as saccadic 
movements using eye-tracking technology, may become useful 
methods of monitoring cerebellar disease in MS (40). Defining 
suitable measures of cerebellar disease burden may be of impor-
tance in the future should disease modifying or symptomatic 
therapies be developed for specific cerebellar issues related to MS.
eXPeRiMenTAL MODeLS OF 
CeReBeLLAR inFLAMMATiOn  
AnD neURODegeneRATiOn
The most well-established animal model for MS is experimental 
autoimmune encephalomyelitis (EAE). It is, however, not without 
its limitations, since many of the features of MS fail to be repli-
cated in the model. Cerebellar inflammation occurs commonly 
during the course of EAE. The specific mode of inducing EAE 
may influence the predilection for cerebellar involvement (41). 
Purkinje cell dysfunction has been show to occur in EAE with 
reduced synaptic function (42). Loss of Purkinje cell and gray 
matter pathology have also been documented in EAE (43). 
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Several models of dysmyelination and non-immune myelin loss 
have been studied. A model of slow, progressive myelin loss in a 
naturally occurring rat mutant is associated with extensive axonal 
changes (spheroid formation and neurofilament dephosphoryla-
tion) within the cerebellum (44).
Ion channel abnormalities in EAE have been noted for some 
time and form the basis for ongoing trials of sodium channel 
blockers in MS. Persistent sodium ion influx into the axon 
(associated with failure of ATP-dependent sodium/potassium 
exchange mechanisms in the context of reduced energy availabil-
ity) leads to reversal of the sodium/calcium exchanger and thus 
excess intra-axonal calcium ions accumulate. Sodium channel 
blockade certainly appears to ameliorate axonal injury in EAE, 
but so far human trials have been less impressive (45). Indeed, 
ion channel abnormalities in Purkinje cells of mice affected by 
EAE have been documented, with aberrant expression of Nav1.8 
channels causing alteration of electrophysiological properties of 
Purkinje cells (28).
The finding of cell fusion in MS cerebellum noted above has 
been postulated as a potential mechanism for Purkinje cell res-
cue in various neurological diseases. Transplantation of human 
mesenchymal stem cells into mice which have subsequently been 
given EAE leads to expression of human markers within the 
cerebellum of the these mice, suggesting that in EAE cell fusion 
occurs (46). Whether this leads to some form of neuroprotection 
in the cerebellum is unclear.
TReATMenTS FOR CeReBeLLAR 
DiSeASe in MS
Treatments for MS fall into the categories of symptomatic treat-
ments for established symptoms and disease-modifying thera-
pies (DMTs), which aim to reduce the burden of disease. The 
design of DMT trials has not sought to determine whether these 
drugs improve cerebellar function specifically. The majority of 
trials have used reduction in annualized relapse rates and EDSS 
scores (as a marker of disability progression). As mentioned 
earlier, the EDSS does have cerebellar function as part of the 
assessment, but its utility in picking out specific effects of drugs 
on cerebellar function is limited. However, cerebellar relapses 
are associated with an increased risk of disability accrual (rela-
tive to some other relapse types, such as sensory) (47). Thus, 
reducing relapses by DMTs is likely to reduce the burden of 
cerebellar disease in the long term. Interestingly, analysis of 
an alemtuzumab trial (CAMSS223 versus beta-interferon) 
demonstrated improvements in the cerebellar FS score of the 
EDSS (48).
Non-pharmacological approaches to MS ataxia are com-
monly employed, of which physiotherapy regimens are the most 
widely accepted. Balance-specific exercises involving soma-
tosensory and motor strategy facilitation are generally employed 
to varying degrees (49). Improving core stability in patients with 
balance problems may be effective, and lumbar stabilization 
exercises (which improve core trunk muscles, leading to effects 
on postural control, ambulation, and skilled motor function) 
are often incorporated into MS rehabilitation programs (50). 
In addition, task-oriented training enhances ambulation and 
postural control in MS patients due to the promotion of motor 
learning (51). In general, combinations of these physiotherapy 
approaches are thought to be most beneficial (52).
Pharmacological approaches to improving ataxic symptoms 
are generally disappointing, and newer therapies are needed. 
The most recent Cochrane review of treatments for ataxia in 
MS (which reviewed six randomized placebo-controlled trials) 
concluded that absolute and comparative efficacy and tolerability 
of pharmacotherapies are poorly documented and no recom-
mendations could be made (53). Small open label studies or case 
reports have suggested benefits for a range of drugs for the treat-
ment of tremor. Isoniazid, propranolol, and levetiracetam have 
been studied, although the data on their use are not convincing 
(the number of patients involved in these trials was generally very 
low, and limited conclusions could be drawn) and they are not 
widely used (54–59). Several randomized controlled trials of can-
nabis extracts have concluded that cannabinoids appear to have 
no beneficial effect on MS tremor (60–62). Paroxysmal ataxia and 
dysarthria have been reported in MS, albeit rarely, and there is 
some suggestion that they may respond to carbamazepine, in a 
similar way to other paroxysmal symptoms of MS, such as tonic 
spasm (63).
The majority of reports of stereotactic surgery in MS tremor 
have targeted thalamic structures with variable results (64, 65). 
In the Cochrane review, one neurosurgical study of thalamotomy 
versus thalamic stimulation was included (53). Tremor was 
abolished by both thalamotomy and thalamic stimulation in all 
patients immediately postsurgery (66). However, tremor returned 
in almost all MS patients after 6 months (albeit of less severity 
than preoperative levels) and general disability scores were 
unchanged. The short-lived nature of the response is seen in other 
studies of surgical treatments of MS tremor (67). Improvement in 
quality of life measures following thalamic stimulation, including 
improvement in ability to feed oneself, has been demonstrated in 
selected cases (68).
There is a great need to improve therapeutic options for 
symptomatic treatments of cerebellar symptoms and to provide 
neuroprotection within the cerebellum. The design of trials 
aimed specifically at cerebellar protection in MS will be chal-
lenging due to the paucity of good outcome measures, although 
improvements in imaging techniques will help. Refinements in 
neurosurgical techniques may help patients with severe ataxic 
tremors. Increased understanding of the pathophysiology of cer-
ebellar disease in MS will aid the search for new drug therapies. 
A number of trials are now being pioneered specifically aimed 
at slowing disease progression. Newer therapies, such a stem cell 
therapies, are being developed. The observation of Purkinje cell 
fusion as a potential neurorestorative mechanism makes the pros-
pect of stem cell treatments for MS cerebellar disease particularly 
attractive.
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